Press Release: Longer-term Novartis Kisqali(R) -2-

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Hurvitz S et al. Distant disease-free survival (DDFS) across key

subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a

nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2- early

breast cancer (EBC). Presented at the San Antonio Breast Cancer Symposium,

December 12, 2024. Texas, USA.

2. Tarantino P et al. Risk of recurrence in real-world (RW) NATALEE- and

monarchE-eligible populations of patients with HR+/HER2- early breast

cancer (EBC) in an electronic health record (EHR)-derived database.

Presented at the San Antonio Breast Cancer Symposium, December 11, 2024.

Texas, USA.

3. NCCN Guidelines. NCCN Clinical Practice Guidelines in Oncology (NCCN

Guidelines(R)) - Breast Cancer. Accessed December

2024. https://www.nccn.org

4. Hortobagyi G, Stroyakovskiy D, Yardley DA, et al. Ribociclib (RIB) +

nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients

with HR+/HER2- early breast cancer: final invasive disease-free survival

(iDFS) analysis from the NATALEE trial. Presented at San Antonio Breast

Cancer Symposium (SABCS); December 8, 2023; San Antonio, USA.

5. Fasching PA. Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase

Inhibitor (NSAI) in Patients (Pts) With HR+/HER2- Early Breast Cancer

(EBC): 4-Year Outcomes from the NATALEE Trial. LBA13. Proffered Paper

presented at the European Society for Medical Oncology Congress,

September 16, 2024. Barcelona, Spain.

6. Campone M et al. Phase I/II study of the novel radioligand therapy

[Lu]Lu-NeoB plus capecitabine in patients with ER+/HER2- advanced breast

cancer (ABC) with GRPR expression after progression on prior endocrine

therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i) for ABC. Presented at the

San Antonio Breast Cancer Symposium, December 12, 2024. Texas, USA.

7. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy

in Early Breast Cancer. N Engl J Med. 2024;390(12):1080-1091.

doi:10.1056/NEJMoa2305488

8. Clinicaltrials.gov. NCT03701334. A Trial to Evaluate Efficacy and Safety

of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients

With HR+/ HER2- Early Breast Cancer (NATALEE). Available from:

https://clinicaltrials.gov/study/NCT03701334. Accessed December 2024.

9. Kisqali. Prescribing Information (US FDA). Novartis Pharmaceuticals

Corporation; 2017. Accessed December 2024.

https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf

10. Kisqali. Summary of product characteristics (SmPC). Novartis Europharm

Limited; 2017. Accessed December 2024.

https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf

11. Yardley DA et al. Pooled exploratory analysis of survival in patients

(pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases

(mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the

MONALEESA (ML) trials. Poster presented at the European Society of

Medical Oncology Congress. September 9-13, 2022. Paris, France.

12. Neven P et al. Updated overall survival (OS) results from the first-line

(1L) population in the Phase III MONALEESA-3 trial of postmenopausal

patients with HR+/HER2- advanced breast cancer (ABC) treated with

ribociclib (RIB) + fulvestrant (FUL). Mini oral presented at the European

Society for Medical Oncology Breast Cancer Congress. May 4, 2022. Paris,

France.

13. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with

Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med.

2022;386(10):942-950. doi:10.1056/NEJMoa2114663

14. Hortobagyi GN et al. Overall survival (OS) results from the phase III

MONALEESA (ML)-2 trial of postmenopausal patients with hormone receptor

positive/human epidermal growth factor receptor 2 negative (HR+/HER2-)

advanced breast cancer (ABC) treated with endocrine therapy (ET) +/-

ribociclib. LBA 17. Proffered paper presented at the European Society of

Medical Oncology Congress, September 16-21, 2021. Lugano, Switzerland.

15. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus

endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316.

doi:10.1056/NEJMoa1903765

16. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus

Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514-524.

doi:10.1056/NEJMoa1911149

17. Slamon DJ et al. Overall survival (OS) results of the Phase III

MONALEESA-3 trial of postmenopausal patients (pts) with hormone

receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-)

advanced breast cancer (ABC) treated with fulvestrant (FUL) +/-

ribociclib (RIB). LBA7_PR. Presented at the European Society of Medical

Oncology Congress, September 29, 2019. Barcelona, Spain.

18. Slamon DJ et al. Updated overall survival (OS) results from the Phase III

MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2-

advanced breast cancer (ABC) treated with fulvestrant (FUL) +/-

ribociclib (RIB). Presented at the American Society of Clinical Oncology

Annual Meeting, June 5, 2021. Chicago, USA.

19. Tripathy D et al. Updated overall survival (OS) results from the phase

III MONALEESA-7 trial of pre- or perimenopausal patients with HR+/HER2-

advanced breast cancer (ABC) treated with endocrine therapy (ET) +/-

ribociclib. Presented at the San Antonio Breast Cancer Symposium,

December 9, 2020. Texas, USA.

20. Yardley D et al. Overall survival (OS) in patients (pts) with advanced

breast cancer (ABC) with visceral metastases (mets), including those with

liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in

the MONALEESA (ML) -3 and -7 trials. Presented at the American Society of

Clinical Oncology Annual Meeting, June 2020. Chicago, USA.

21. O'Shaughnessy J et al. Overall survival subgroup analysis by metastatic

site from the Phase III MONALEESA-2 study of first-line ribociclib +

letrozole in postmenopausal patients with HR+/HER2- advanced breast

cancer. Presented at the San Antonio Breast Cancer Symposium, December

7-10, 2021. Texas, USA.

22. European Society of Medical Oncology (ESMO). ESMO MCBS scorecards;

(MORE TO FOLLOW) Dow Jones Newswires

December 10, 2024 09:00 ET (14:00 GMT)